Jay Barth

3.8k citations

69 papers · 1.3k indexed · h-index 18

Impact in

Gastroenterology top 2%
- Gastroesophageal reflux and treatments
Physiology top 10%
- Lysosomal Storage Disorders Research

Papers in ⓘ

Gastroenterology 12
- Gastroesophageal reflux and treatments 12
Physiology 24
- Lysosomal Storage Disorders Research 21

Co-authors: A. Reha (10 shared papers)Gary Elfring (9 shared papers)Nimish Vakil (4 shared papers)François Lanza (1 shared paper)Howard Schwartz (1 shared paper)Stuart W. Peltz (5 shared papers)Richard T. Abresch (3 shared papers)Craig M. McDonald (4 shared papers)
Journals: Molecular Genetics and Metabolism (15 papers)Gastroenterology (6 papers)Alimentary Pharmacology & Therapeutics (5 papers)Neuromuscular Disorders (4 papers)Orphanet Journal of Rare Diseases (3 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Jay Barth

63 papers receiving 1.3k citations

Peers

Countries citing papers authored by Jay Barth

Since Specialization

Citations

This map shows the geographic impact of Jay Barth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Barth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Barth more than expected).

Fields of papers citing papers by Jay Barth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Barth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Barth. The network helps show where Jay Barth may publish in the future.

Co-authors

The 25 scholars most cited alongside Jay Barth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jay Barth Line = papers co-authored together Jay Barth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study Muscle & Nerve ·Craig M. McDonald, Erik Henricson, Richard T. Abresch, Julaine Florence, Michelle Eagle, Eduard Gappmaier, Allan M. Glanzman, (unknown), Robert J. Spiegel, Jay Barth, Gary Elfring, A. Reha, Stuart W. Peltz	2013	224
2	Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy PLoS ONE ·Richard S. Finkel, Kevin M. Flanigan, Brenda Wong, Carsten G. Bönnemann, Jacinda B. Sampson, H. Lee Sweeney, A. Reha, Valerie Northcutt, Gary Elfring, Jay Barth, Stuart W. Peltz	2013	172
3	Seven‐day therapy for Helicobacter pylori in the United States Alimentary Pharmacology & Therapeutics ·Nimish Vakil, François Lanza, Howard Schwartz, Jay Barth	2004	140
4	Colorectal Adenocarcinoma in Crohn's Disease Annals of Surgery ·M B Ribeiro, Adrian J. Greenstein, David B. Sachar, Jay Barth, Sankar Balasubramanian, Noam Harpaz, Tomas M. Heimann, Arthur H. Aufses	1996	77
5	Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study Genetics in Medicine ·Dominique P. Germain, Kathy Nicholls, Roberto Giugliani, Daniel G. Bichet, Derralynn Hughes, Laura Barisoni, Robert B. Colvin, J. Charles Jennette, Nina Skuban, Jeffrey P. Castelli, Elfrida R. Benjamin, Jay Barth, Christopher Viereck	2019	71
6	Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational Influences PLoS Currents ·Erik Henricson, Richard T. Abresch, Jay J. Han, Alina Nicorici, Erica Goude Keller, Gary Elfring, A. Reha, Jay Barth, Craig M. McDonald	2012	57
7	Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study Molecular Genetics and Metabolism ·Ulla Feldt‐Rasmussen, Derralynn Hughes, Gere Sunder‐Plassmann, Suma P. Shankar, Khan Nedd, Iacopo Olivotto, Damara Ortiz, Toya Ohashi, Takashi Hamazaki, Nina Skuban, Julie Yu, Jay Barth, Kathy Nicholls	2020	53
8	Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase PLoS ONE ·David G. Warnock, Daniel G. Bichet, Myrl Holida, Özlem Göker-Alpan, Kathy Nicholls, Mark Thomas, François Eyskens, Suma P. Shankar, Mathews Adera, Sheela Sitaraman, Richie Khanna, John J. Flanagan, Brandon A. Wustman, Jay Barth, Carrolee Barlow, Kenneth J. Valenzano, David J. Lockhart, Pol Boudes, Franklin K. Johnson	2015	49
9	Long‐term prevention of erosive or ulcerative gastro‐oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5‐year study in the United States Alimentary Pharmacology & Therapeutics ·Antonio Caos, Jeffrey R. Breiter, Carlos Perdomo, Jay Barth	2005	39
10	Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment Journal of Medical Genetics ·Michael Mauer, Alexey Sokolovskiy, Jay Barth, Jeffrey P. Castelli, Hadis Williams, Elfrida R. Benjamin, Behzad Najafian	2017	35
11	Integrated acidity and rabeprazole pharmacology Alimentary Pharmacology & Therapeutics ·Jerry D. Gardner, Carlos Perdomo, S Sloan, William F. Hahne, Jay Barth, S. Rodriguez‐Stanley, Malcolm Robinson	2002	33
12	A prospective study of the accuracy of preoperative computed tomographic staging of patients with biopsy-proven rectal carcinoma Diseases of the Colon & Rectum ·Brenda Shank, D. David Dershaw, James F. Caravelli, Jay Barth, Warren E. Enker	1990	31
13	Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease The American Journal of Gastroenterology ·Antonio Caos, Moti Moskovitz, Yogeshwar Dayal, Carlos Perdomo, Robert Niecestro, Jay Barth	2000	28
14	Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial Orphanet Journal of Rare Diseases ·Raphael Schiffmann, Daniel G. Bichet, Ana Jovanović, Derralynn Hughes, Roberto Giugliani, Ulla Feldt‐Rasmussen, Suma P. Shankar, Laura Barisoni, Robert B. Colvin, J. Charles Jennette, Fred Holdbrook, Andrew E. Mulberg, Jeffrey P. Castelli, Nina Skuban, Jay Barth, Kathy Nicholls	2018	25
15	Free colonic perforation without dilatation in ulcerative colitis The American Journal of Surgery ·Adrian J. Greenstein, Jay Barth, David B. Sachar, Arthur H. Aufses	1986	25
16	Chorioamniotic membrane separation following fetal myelomeningocele repair: incidence, risk factors and impact on perinatal outcome Ultrasound in Obstetrics and Gynecology ·R. Corroënne, M. Yepez, Jay Barth, Evelyn Pan, William E. Whitehead, Jimmy Espinoza, Alireza A. Shamshirsaz, Ahmed A. Nassr, Michael A. Belfort, Magdalena Sanz Cortés	2019	19
17	Rabeprazole‐based therapy in Helicobacter pylori eradication Alimentary Pharmacology & Therapeutics ·Jay Barth, William F. Hahne	2002	18
18	Rabeprazole is superior to omeprazole for the inhibition of peptone meal‐stimulated gastric acid secretion in Helicobacter pylori‐negative subjects Alimentary Pharmacology & Therapeutics ·Gordon Ohning, John H. Walsh, Joseph R. Pisegna, Anita Murthy, Jay Barth, T. O. G. Kovacs	2003	17
19	Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. PubMed ·Shashank Rohatagi, Günther Hochhaus, Helmut Möllmann, Jay Barth, Hartmut Derendorf	1995	17
20	Amebic liver abscess: a study of 11 cases compared with a series of 38 patients with pyogenic liver abscess. PubMed ·Greenstein Aj, Jay Barth, Adam P. Dicker, Bottone Ej, Aufses Ah	1985	16

About Jay Barth

Jay Barth is a scholar working on Gastroenterology, Physiology, Rheumatology, Behavioral Neuroscience and Biological Psychiatry, having authored 69 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (21 papers), Helicobacter pylori-related gastroenterology studies (14 papers), Gastroesophageal reflux and treatments (12 papers), Glycogen Storage Diseases and Myoclonus (9 papers), Carbohydrate Chemistry and Synthesis (8 papers), Muscle Physiology and Disorders (7 papers), Eosinophilic Esophagitis (6 papers) and Child Nutrition and Feeding Issues (3 papers). The work is most often cited by research in Gastroenterology (217 citations), Physiology (329 citations), Genetics (112 citations), Surgery (416 citations) and Cell Biology (124 citations). Jay Barth has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include A. Reha, Gary Elfring, Nimish Vakil, François Lanza, Howard Schwartz, Stuart W. Peltz, Richard T. Abresch, Craig M. McDonald, Erik Henricson and Carlos Perdomo. Their work appears in journals such as Molecular Genetics and Metabolism, Gastroenterology, Alimentary Pharmacology & Therapeutics, Neuromuscular Disorders and Orphanet Journal of Rare Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact